Status Update and Interim Results from the Asymptomatic Carotid Surgery Trial-2 (ACST-2)  by unknown
Selected Abstracts from the November Issue of the
European Journal of Vascular and Endovascular Surgery
Jean-Baptiste Ricco, MD, PhD, Editor-in-Chief, and A. Ross Naylor, MBChB,MD, FRCS, Senior EditorStatus Update and Interim Results from the Asymptomatic Carotid
Surgery Trial-2 (ACST-2)
ACST-2 Collaborative Group. Eur J Vasc Endovasc Surg 2013;46:510-8.
Objectives: ACST-2 is currently the largest trial ever conducted to
compare carotid artery stenting (CAS) with carotid endarterectomy
(CEA) in patients with severe asymptomatic carotid stenosis requiring
revascularization.
Methods: Patients are entered into ACST-2 when revascularization is
felt to be clearly indicated, when CEA and CAS are both possible, but where
there is substantial uncertainty as to which is most appropriate. Trial
surgeons and interventionalists are expected to use their usual techniques
and CE-approved devices. We report baseline characteristics and blinded
combined interim results for 30-day mortality and major morbidity for
986 patients in the ongoing trial up to September 2012.
Results: A total of 986 patients (687men, 299women),mean age 68.7
years (SD6 8.1) were randomized equally to CEA or CAS. Most (96%) had
ipsilateral stenosis of 70-99% (median 80%) with contralateral stenoses of 50-
99% in 30% and contralateral occlusion in 8%. Patients were on appropriate
medical treatment. For 691 patients undergoing intervention with at least
1-month follow-up and Rankin scoring at 6months for any stroke, the overall
serious cardiovascular event rate of periprocedural (within 30 days) disabling
stroke, fatal myocardial infarction, and death at 30 days was 1.0%.
Conclusions: Early ACST-2 results suggest contemporary carotid
intervention for asymptomatic stenosis has a low risk of serious morbidity
and mortality, on par with other recent trials. The trial continues to recruit,
to monitor periprocedural events and all types of stroke, aiming to
randomize up to 5000 patients to determine any differential outcomes
between interventions.
Procedural Risk Following Carotid Endarterectomy in the Hyperacute
Period after Onset of Symptoms
Sharpe R., Sayers R.D., London N.J.M., Bown M.J., McCarthy M.J.,
Nasim A., Davies R.S.M., Naylor A.R. Eur J Vasc Endovasc Surg
2013;46:519-24.
Objectives: There have been concerns that performing carotid endar-
terectomy (CEA) in the hyperacute period after onset of a transient ischae-
mic attack (TIA) or stroke may be associated with a signiﬁcant increase in
the procedural risk that could offset any long-term beneﬁt to the patient.
The aim of this audit was to determine the 30-day risk of stroke/death after
CEA in symptomatic patients, stratiﬁed for delay from the most recent
neurological event, mode of presentation, and age.
Methods: Retrospective audit in 475 recently symptomatic patients
between October 1, 2008, and April 24, 2013.
Results: Forty-one patients (9%) underwent surgery <48 hours of
their most recent event, with a 30-day death/stroke rate of 2.4% (1/41).
The procedural risk was 1.8% in 167 patients who underwent surgery within
3-7 days (3/167), falling to 0.8% in 133 patients who underwent surgery
between 8 and 14 days (1/133) and 0.8% in 134 patients whose surgery
took place after >14 days had elapsed (1/134). Overall, 208 (44%) under-
went surgery within 7 days of their most recent neurological event (30-day
risk = 1.9%), while 341 (72%) underwent CEA within 14 days (30 day risk =
1.5%). There was no evidence of any systematic differences in procedural
risk by operating in the hyperacute period relating to mode of presentation
(TIA, stroke, amaurosis) or age (<80 years; >80 years).
Conclusions: This audit found no evidence that the procedural risk
was increased when CEA was performed in the hyperacute period whether
this time period was deﬁned as <48 hours, <7 days, or <14 days.
Calciﬁcationas aRiskFactor forRuptureofAbdominalAorticAneurysm
Buijs R.V.C., Willems T.P., Tio R.A., Boersma H.H., Tielliu I.F.J.,
Slart R.H.J.A., Zeebregts C.J. Eur J Vasc Endovasc Surg 2013;46:542-8.
Objectives: Abdominal aortic aneurysm (AAA) is a major cause of
death in developed countries. The AAA diameter is still the only validated
prognostic measure for rupture, and therapeutic interventions are initiated
accordingly. This still leads to unnecessary interventions in some cases or1426unidentiﬁed impending ruptures. Vascular calciﬁcation has been validated
abundantly as a risk factor in the cardiovascular ﬁeld and may strengthen
the rupture risk assessment of the AAA. With this study we aim to assess
the correlation between AAA calciﬁcation and rupture risk in a retrospective
unmatched case-control population.
Methods: A database of 334 AAA patients was evaluated. Three
groups were formed: elective (eAAA; n = 233), ruptured (rAAA; n = 73)
and symptomatic non-ruptured (sAAA; n = 28) AAA patients. The Abdom-
inal Aortic Calciﬁcation-8 score (AAC-8) was used to measure the severity
of vascular calciﬁcation.
Results: The AAA diameter (616 12 mm vs 746 21 mm; P < .001)
and AAC-8 score (3.4 6 2 points vs 4.9 6 2.3 points; P < .001) of the
eAAA and the combined rAAA and sAAA groups, respectively, were signif-
icantly different after univariate analysis. Multivariate analysis showed that
larger AAA diameter (odds ratio [OR]: 1.048/mm increase; 95% conﬁ-
dence interval [CI]: 1.042-1.082; P < .001) and a higher AAC-8 score
(OR: 1.34/point increase; 95% CI: 1.19-1.53; P < .001) were signiﬁcantly
associated with development into a sAAA or rAAA. Peripheral artery disease
was signiﬁcantly correlated to eventual elective treatment (OR: 0.39; 95%
CI: .15-1; P = .049).
Conclusion: This study suggests a trend of an increased degree of
calciﬁcation in symptomatic or even ruptured AAA patients compared
with elective AAA patients.
Localized Argyria Caused by Metallic Silver Aortic Grafts: A Unique
Adverse Effect
Berger P., Ricco J.B., Liqui Lung P., Moll F.L. Eur J Vasc Endovasc Surg
2013;46:565-8.
Introduction: Silver-coated grafts are designed to prevent vascular graft
infections. Silver is a safe element but toxic effects have been reported. We
describe two cases of possible localized argyria after silver graft implantation.
Report: Two patients presented with perigraft groin collections after
implantation of silver grafts. During reoperation, an ashen-grey necrotic
substance was seen surrounding the grafts. The grafts were explanted and
lower limb perfusion restored. Cultures were negative and both patients
had uneventful recoveries.
Discussion: Our cases are highly suggestive of a possible unique
adverse effect: a combination of localized silver toxicity and neutrophilic
mediated tissue destruction.
Duplex-guided Percutaneous Transluminal Angioplasty in Iliac
Arterial Occlusive Disease
Krasznai A.G., Sigterman T.A., Welten R.J., Heijboer R., Sikkink C.J.J.M.,
van de Akker L.H.J.M., Bouwman L.H. Eur J Vasc Endovasc Surg
2013;46:583-7.
Background: Chronic renal insufﬁciency (CRI) is a growing global
problem. PTA can be performed without nephrotoxic contrast, utilizing
Doppler-ultrasound (Duplex) guidance.
Duplex-guided infra-inguinal interventions and access-related inter-
ventions have been reported. Duplex-guided iliac interventions have not
been performed to any extent because of the anatomic location. In our
study we evaluated the safety and efﬁcacy of Duplex-guided percutaneous
transluminal angioplasty (DuPTA) in iliac arteries.
Methods: From June 2012 until February 2013, 31 patients (35 iliac
lesions), underwent DuPTA. Indications ranged from Rutherford 3 to 5.
Preoperative evaluation included Ankle Brachial Index (ABI), Duplex and
MRA. Procedural success was deﬁned as crossing the lesion with a guidewire
and dilating or stenting the lesion. Clinical success was deﬁned as 50%
reduction in peak systolic velocity (PSV) or clinical improvement. PSV
was evaluated after PTA, then at 2 weeks. Clinical results were assessed 2
weeks after the procedure.
Results: Procedural success was achieved in 94% of patients (33/35),
all of whom also had clinical success. Post-procedural PSV reduction
showed an average improvement of 63% (431 cm/s to 153 cm/s). Mean
preoperative ABI was 0.72 and improved to 0.88 postoperatively.
